-
公开(公告)号：EP2961412A4
公开(公告)日：2016-11-09
申请号：EP14756693
申请日：2014-02-26
发明人： WHITE THOMAS F , SMITH STEVEN
IPC分类号： A61K31/7034 , A61K31/517 , A61K31/5377 , A61K31/661 , A61K45/06 , C07F9/12 , C07H15/20 , C07H15/203
CPC分类号： C07H15/20 , A61K31/517 , A61K31/5377 , A61K31/661 , A61K31/662 , A61K31/7012 , A61K31/7034 , A61K45/06 , C07F9/12 , C07H15/203 , A61K2300/00
摘要： The present application relates to compositions and methods for treating a proliferative disorder by administering to a subject a pharmaceutical composition of a dual kinase inhibitor metabolite. Catecholic butane metabolites can serve as dual kinase inhibitors for purposes of methods described herein.
-
-
公开(公告)号：EP2349235A1
公开(公告)日：2011-08-03
申请号：EP09752638.8
申请日：2009-11-06
IPC分类号： A61K31/065 , A61P35/00
CPC分类号： A61K31/05 , A61K31/00 , A61K31/065 , A61K31/09 , A61K31/225 , A61K45/06 , C12Q1/6886 , G01N33/57492 , G01N33/74
摘要： The present application relates to compositions and methods for treating a proliferative disorder by administering to a subject a pharmaceutical composition of a dual kinase inhibitor. Catecholic butanes can serve as dual kinase inhibitors for purposes of methods described herein. Subjects can be further treated by co-administering an EGFR inhibitor. The present application also relates to analyzing a sample with respect to levels of IGF-IR and EGFR and comparing levels of IGF-IR and EGFR to a control. Patients can be selected for treatment with a catecholic butane based on the assessment; optionally, patients can be further treated with an EGFR inhibitor, an IGF-IR inhibitor, or both.
-
公开(公告)号：EP3044593A4
公开(公告)日：2017-05-17
申请号：EP14842383
申请日：2014-09-09
发明人： WHITE THOMAS F , HOTH DANIEL
IPC分类号： G01N33/574 , A61K31/282 , A61K31/403 , A61K31/47 , A61K31/506 , A61K31/517 , A61K31/53 , A61K31/5377 , A61K33/24 , A61K45/06
CPC分类号： A61K45/06 , A61K31/282 , A61K31/403 , A61K31/47 , A61K31/506 , A61K31/517 , A61K31/53 , A61K31/5377 , A61K33/24 , A61K2300/00
-
公开(公告)号：EP3044593A1
公开(公告)日：2016-07-20
申请号：EP14842383.3
申请日：2014-09-09
发明人： WHITE, Thomas, F. , HOTH, Daniel
IPC分类号： G01N33/574
CPC分类号： A61K45/06 , A61K31/282 , A61K31/403 , A61K31/47 , A61K31/506 , A61K31/517 , A61K31/53 , A61K31/5377 , A61K33/24 , A61K2300/00
摘要： The present application relates to compositions and methods for treating a proliferative disorder by administering to a subject a pharmaceutical composition of a dual kinase inhibitor. Catecholic butanes cane serve as dual kinase inhibitors for purposes of methods described herein. Patients to be treated include those that have been treated with Tarceva or other therapeutic compounds and relapsed or are resistant to treatment. The compounds described herein may exhibit a synergistic effect when administered with another agent.
摘要翻译： 本申请涉及通过向受试者施用双激酶抑制剂的药物组合物来治疗增殖性病症的组合物和方法。 出于本文所述的方法的目的，儿茶酚丁烷甘蔗充当双激酶抑制剂。 要治疗的患者包括那些已经用特罗凯或其他治疗化合物治疗并且复发或耐受治疗的患者。 当与另一种药剂一起施用时，本文所述的化合物可以表现出协同效应。
-
公开(公告)号：EP3687501A1
公开(公告)日：2020-08-05
申请号：EP18860672.7
申请日：2018-09-28
发明人： WHITE, Thomas F. , NAVA, Stephen M.
-
公开(公告)号：EP3654958A1
公开(公告)日：2020-05-27
申请号：EP18820013.3
申请日：2018-06-22
发明人： WHITE, Thomas F.
IPC分类号： A61K31/02 , A61K31/04 , A61K31/166 , C07C205/06 , C07C233/65 , G01N33/574
-
公开(公告)号：EP2961412A1
公开(公告)日：2016-01-06
申请号：EP14756693.9
申请日：2014-02-26
发明人： WHITE, Thomas, F. , SMITH, Steven
IPC分类号： A61K31/7034
CPC分类号： C07H15/20 , A61K31/517 , A61K31/5377 , A61K31/661 , A61K31/662 , A61K31/7012 , A61K31/7034 , A61K45/06 , C07F9/12 , C07H15/203 , A61K2300/00
摘要： The present application relates to compositions and methods for treating a proliferative disorder by administering to a subject a pharmaceutical composition of a dual kinase inhibitor metabolite. Catecholic butane metabolites can serve as dual kinase inhibitors for purposes of methods described herein.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.014 秒)
